ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $15.46 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

ARS Pharmaceuticals Price Performance

SPRY stock opened at $12.31 on Thursday. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -24.14 and a beta of 1.04. The business’s fifty day moving average price is $11.93 and its two-hundred day moving average price is $13.09. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

Wall Street Analyst Weigh In

SPRY has been the topic of several analyst reports. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 target price on the stock. Leerink Partners increased their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. William Blair reissued an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Raymond James increased their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Scotiabank initiated coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $31.00.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the completion of the transaction, the insider now directly owns 1,098,499 shares in the company, valued at $12,819,483.33. This trade represents a 8.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.31, for a total value of $615,500.00. Following the transaction, the director now owns 210,346 shares of the company’s stock, valued at $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 276,872 shares of company stock worth $3,222,416. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.